Information in the news releases is current on the date of the announcement, but is subject to change without prior notice.
-
December 24, 2019
GILEAD AND EISAI ENTER INTO AGREEMENT IN JAPAN FOR THE CO-PROMOTION OF THE INVESTIGATIONAL RHEUMATOID ARTHRITIS THERAPY FILGOTINIB, PENDING REGULATORY APPROVAL
Agreement Extends to Additional Potential Indications for Filgotinib, Including Ulcerative Colitis, Crohn’s Disease and Psoriatic Arthritis
-
December 23, 2019
U.S. FDA APPROVES EISAI’S DAYVIGO™ (LEMBOREXANT) FOR TREATMENT OF INSOMNIA IN ADULT PATIENTS
OREXIN RECEPTOR ANTAGONIST PROVEN EFFECTIVE FOR BOTH SLEEP ONSET AND SLEEP MAINTENANCE IN CLINICAL DEVELOPMENT PROGRAM OF MORE THAN 2,000 PATIENTS
-
December 10, 2019
COMMENCEMENT OF MAJOR RENOVATION OF TSUKUBA RESEARCH LABORATORIES AS EISAI GLOBAL DRUG DISCOVERY CENTER AIMING FOR CONNECTING HUMAN AND HUMAN, AND DATA, AND THE WORLD
-
December 9, 2019
Sysmex Presents Academic Report with a View to Creating a Simple Method of Diagnosing Alzheimer’s Disease Using Blood
Presenting the Most Recent Data at the 12th Clinical Trials on Alzheimer’s Disease (CTAD) Conference
-
December 6, 2019
EISAI SATISFIES ALL-CASE SURVEILLANCE CONDITION FOR APPROVAL OF ANTI-CANCER AGENT LENVIMA® IN TREATMENT OF THYROID CANCER
-
December 5, 2019
EISAI TO PRESENT NEW RESEARCH ON ERIBULIN (HALAVEN®) AT 42ND ANNUAL SAN ANTONIO BREAST CANCER SYMPOSIUM
-
December 2, 2019
EISAI TO PRESENT LATEST DATA ON ALZHEIMER’S DISEASE / DEMENTIA PIPELINE AT 12TH CLINICAL TRIALS ON ALZHEIMER’S DISEASE CONFERENCE
-
December 2, 2019
ADDITIONAL INDICATION FOR LENVIMA® (LENVATINIB) FOR DIFFERENTIATED THYROID CANCER ACCEPTED IN CHINA
-
November 29, 2019
INVESTIGATION REPORT BY MINISTRY OF HEALTH, LABOUR AND WELFARE FOR FATAL CASE IN PHASE I CLINICAL STUDY FOR E2082
-
November 26, 2019
EISAI TO PRESENT LATEST DATA ON PERAMPANEL AT 73RD AMERICAN EPILEPSY SOCIETY ANNUAL MEETING
-
November 20, 2019
PARKINSON’S DISEASE TREATMENT EQUFINA® 50MG TABLETS (SAFINAMIDE MESILATE) LAUNCHED IN JAPAN
-
November 5, 2019
EISAI TRANSFERS RIGHTS TO RECEIVE ROYALTIES OUTSIDE OF JAPAN FOR EZH2 INHIBITOR TAZEMETOSTAT TO ROYALTY PHARMA
-
October 31, 2019
EISAI SUPPORTS RELIEF EFFORTS FOR TYPHOON HAGIBIS
-
October 22, 2019
Biogen Plans Regulatory Filing for Aducanumab in Alzheimer’s Disease Based on New Analysis of Larger Dataset from Phase 3 Studies
-
October 15, 2019
NEW DRUG APPROVAL FOR FYCOMPA® FOR ADJUNCTIVE TREATMENT OF PARTIAL ONSET SEIZURES IN CHINA
-
October 1, 2019
Final Study Results Evaluating LENVIMA® (lenvatinib) Plus KEYTRUDA® (pembrolizumab) Combination Treatment in Advanced Endometrial Cancer Presented at ESMO 2019 Congress
-
September 30, 2019
EISAI AND NICHI-IKO ENTER INTO COLLABORATION AGREEMENT FOR GENERIC PHARMACEUTICAL BUSINESS IN CHINA
-
September 26, 2019
EISAI AND TOKIO MARINE NICHIDO ENTER INTO BUSINESS ALLIANCE FOR CO-EXISTENCE AND PREVENTION OF DEMENTIA
-
September 26, 2019
EISAI AND FRONTEO TO LAUNCH COROBAN®
TUMBLING AND FALLING PREDICTION SYSTEM FOR INPATIENTS
-
September 24, 2019
EISAI TO PRESENT ABSTRACTS ON ONCOLOGY PRODUCTS AND PIPELINE AT ESMO 2019 CONGRESS
-
September 20, 2019
EISAI AND MEIJI ANNOUNCE PARKINSON’S DISEASE TREATMENT EQUFINA® TABLETS (SAFINAMIDE MESILATE) APPROVED IN JAPAN
-
September 20, 2019
PROMOTION AND DISTRIBUTION AGREEMENT WITH MYLAN INDIA FOR ERIBULIN SECOND BRAND IN INDIA
AIMING TO EXPAND AVAILABILITY TO PATIENTS IN INDIA WITH TWO BRANDS HALAVEN® AND TECERIS®
-
September 19, 2019
EISAI TO PRESENT LATEST DATA ON LEMBOREXANT AT WORLD SLEEP CONGRESS
-
September 18, 2019
EISAI SELECTED FOR MEMBERSHIP IN DOW JONES SUSTAINABILITY
ASIA PACIFIC INDEX 2019 FOR SIXTH TIME
-
September 18, 2019
FDA Approves LENVIMA® (lenvatinib) plus KEYTRUDA® (pembrolizumab) Combination Treatment for Patients with Certain Types of Endometrial Carcinoma
Combination Treatment Approved for Patients with Advanced Endometrial Carcinoma That Is Not Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Who Have Disease Progression Following Prior Systemic Therapy and Are Not Candidates for Curative Surgery or Radiation
Under New FDA-Initiated Program, Combination Treatment Is the First to Receive Simultaneous Review Decisions in the U.S., Australia and Canada
-
September 17, 2019
EISAI RECEIVES IIA JAPAN CHAIRMAN’S AWARD OF INSTITUTE OF INTERNAL AUDITORS - JAPAN
-
September 13, 2019
EISAI AND BIOGEN TO DISCONTINUE PHASE III CLINICAL STUDIES OF BACE INHIBITOR ELENBECESTAT IN EARLY ALZHEIMER’S DISEASE
Discontinuation of studies based on Data Safety Monitoring Board recommendation
-
August 29, 2019
ALCOHOL-FREE WIPE FOR ELIMINATING VIRUSES AND BACTERIA ON PERSONAL BELONGINGS
EISAI TO LAUNCH NEW “ETAK® ANTIMICROBIAL WET WIPES” WITH ONE WEEK LASTING ANTIMICROBIAL ACTION
-
August 28, 2019
EISAI ENTERS INTO BUSINESS ALLIANCE WITH COGSTATE FOR EXCLUSIVE DEVELOPMENT AND COMMERCIALIZATION OF A DIGITAL TOOL FOR SELF-ASSESSMENT OF COGNITIVE FUNCTION IN JAPAN
-
August 27, 2019
EISAI PROVIDES TANKS TO SUPPLY CLEAN WATER TO NEGLECTED TROPICAL DISEASES ENDEMIC REGIONS IN KENYA, IN COLLABORATION WITH MERCK
-
August 1, 2019
ALWAYS CLOSE TO YOU. QUICKLY ABSORBING AND NON STICKY
EISAI TO REFRESH AND LAUNCH SAHNE® CREAM AFTER 20 YEARS
WITH MILD SCENT AND NEW PACKAGE
-
July 31, 2019
Notice Regarding Revisions of Dividend Forecasts for Fiscal Year Ending March 31, 2020 (DIVIDEND INCREASE)
-
July 30, 2019
Fatality in Phase I Clinical Study of E2082
-
July 23, 2019
Eisai and Merck & Co., Inc., Kenilworth, N.J., U.S.A. Receive Breakthrough Therapy Designation from FDA for LENVIMA® (lenvatinib) plus KEYTRUDA® (pembrolizumab) Combination Treatment
as Potential First-Line Treatment of Patients with Advanced Unresectable Hepatocellular Carcinoma Not Amenable to Locoregional Treatment
-
July 19, 2019
LATEST TRENDS OF TREATMENT FOR ALZHEIMER’S DISEASE IN SESSIONS AND SYMPOSIUM AT ALZHEIMER’S ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2019
-
July 19, 2019
EISAI PRESENTS DATA SHOWING QUANTIFICATION OF TAU MICROTUBULE BINDING REGION IN CEREBROSPINAL FLUID AND THE IDENTIFICATION OF A TARGET ENGAGEMENT BIOMARKER FOR THE NEW ANTI-TAU ANTIBODY E2814 AT ALZHEIMER’S ASSOCIATION INTERNATIONAL CONFERENCE (AAIC)2019
-
July 18, 2019
EISAI PRESENTS RESEARCH EVALUATING CORRELATION OF HIGHLY-PRECISELY MEASURED AMYLOID BETA IN PLASMA AND CEREBROSPINAL FLUID WITH NEWLY DEVELOPED AUTOMATED PROTEIN ASSAY SYSTEM AT ALZHEIMER’S ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2019
-
July 18, 2019
EISAI PRESENTS NONCLINICAL RESEARCH RESULTS OF ELENBECESTAT OF WITHOUT SIGNIFICANT EFFECTS ON SYNAPTIC FUNCTION IN BRAIN BY SPINAL DENSITIY EVALUATION AT EFFECTIVE DOSE TO DECREASE AMYLOID BETA LEVEL IN CEREBROSPINAL FLUID AT AAIC 2019
-
July 17, 2019
ANTICANCER AGENT HALAVEN® APPROVED FOR TREATMENT OF LOCALLY ADVANCED OR METASTATIC BREAST CANCER IN CHINA
-
July 11, 2019
EISAI LISTED FOR 18TH CONSECUTIVE YEAR IN FTSE4GOOD INDEX SERIES, AN INDEX FOR SOCIALLY RESPONSIBLE INVESTMENT
-
July 11, 2019
LATEST DATA ON EISAI’S ALZHEIMER’S DISEASE / DEMENTIA PIPELINE TO BE PRESENTED AT ALZHEIMER’S ASSOCIATION INTERNATIONAL CONFERENCE (AAIC) 2019
-
July 10, 2019
EISAI CENTER FOR GENETICS GUIDED DEMENTIA DISCOVERY COMMENCES FULL-SCALE OPERATION TOWARD INNOVATIVE DEMENTIA TREATMENTS WITH NEW DRUG DISCOVERY APPROACH IN CAMBRIDGE, MASSACHUSETTS
A FOCUSED DRUG DISCOVERY APPROACH THAT INTEGRATES HUMAN GENETICS / DATA SCIENCE / PRECISION CHEMISTRY
-
July 8, 2019
EISAI ENTERS INTO COLLABORATION RESEARCH AGREEMENT WITH UNIVERSITY OF DUNDEE ON TARGETED PROTEIN DEGRADATION TOWARD CANCER DRUG DISCOVERY
-
June 27, 2019
Position and Policy Regarding Reduction in the Trading Unit of the Company's Shares
-
June 21, 2019
SHELF REGISTRATION FOR ISSUANCE OF STOCK OPTIONS
-
June 20, 2019
CONTINUATION OF “POLICY FOR PROTECTION OF THE COMPANY’S CORPORATE VALUE AND COMMON INTERESTS OF SHAREHOLDERS (COUNTERMEASURES AGAINST TAKEOVERS)”
-
June 17, 2019
TOTAL SYNTHESIS AND NONCLINICAL STUDY RESULTS OF A NOVEL ANTICANCER DRUG CANDIDATE E7130 DERIVED FROM TOTAL SYNTHESIS OF HALICHONDRIN FOUND IN JOINT RESEARCH BETWEEN EISAI AND HARVARD UNIVERSITY SCIENTISTS, PUBLISHED IN SCIENTIFIC REPORTS
-
June 14, 2019
EISAI TO PRESENT LATEST DATA ON PERAMPANEL AT 33RD INTERNATIONAL EPILEPSY CONGRESS
-
May 29, 2019
EISAI TO PRESENT LATEST DATA ON LEMBOREXANT INCLUDING INTEGRATED ANALYSIS OF PHASE III CLINICAL STUDIES AT 33RD ANNUAL SLEEP MEETING
-
May 17, 2019
“SCIENCE BASED TARGETS (SBT) INITIATIVE” APPROVES EISAI’S GREENHOUSE GAS REDUCTION TARGETS
-
May 16, 2019
EISAI TO PRESENT DATA ON ONCOLOGY PIPELINE AND PRODUCTS AT 55TH ASCO ANNUAL MEETING
-
May 13, 2019
Notification Regarding the Disposal of Treasury Stock through Third-Party Allotment in Accordance with the Continuation of the Performance-Related Stock-Based Compensation System
-
May 13, 2019
Notification Regarding the Continuation of the Performance-Related Stock-Based Compensation System
-
May 13, 2019
Notification Regarding Change in Representative Corporate Officers
-
May 10, 2019
EISAI ENTERS INTO LICENSING AGREEMENT WITH MEDAC CONCERNING ANTI-RHEUMATIC AGENT METHOTREXATE SUBCUTANEOUS INJECTION IN JAPAN
-
May 10, 2019
Alzheimer’s Clinical Trials Consortium Selects Elenbecestat and BAN2401 for Upcoming Clinical Studies on Prevention of Alzheimer’s Disease
-
May 9, 2019
Eisai and Allm Enter Into Capital and Business Alliance Agreement for ICT Healthcare Solutions
-
May 9, 2019
EISAI COMMENCES VENTURE INVESTMENT BUSINESS AIMED AT ACCELERATING INNOVATION IN DRUG CREATION AND ESTABLISHMENT OF ECOSYSTEM PLATFORM
-
May 8, 2019
EISAI AND UK DEMENTIA RESEARCH INSTITUTE JOINTLY LAUNCH NEW POST-DOCTORAL PROGRAMME TO ACCELERATE DEMENTIA RESEARCH
-
May 1, 2019
EISAI BUYS OUT PURDUE RIGHTS TO END COLLABORATION
EISAI TO CONTINUE TO DEVELOP AND COMMERCIALIZE LEMBOREXANT GLOBALLY
-
April 24, 2019
EISAI TO PRESENT LATEST DATA ON LEMBOREXANT AND PERAMPANEL AT ANNUAL AMERICAN ACADEMY OF NEUROLOGY MEETING
-
April 24, 2019
EISAI SELECTED AS COMPETITIVE ICT STRATEGY COMPANY 2019
RECOGNIZED FOR TAKING ON CHALLENGE OF TRANSFORMATION TO NEW BUSINESS MODELS BY INTEGRATING MANAGEMENT AND ICT STRATEGIES
-
April 8, 2019
JAPAN MHLW GRANTS SAKIGAKE DESIGNATION TO NOVEL FIBROBLAST GROWTH FACTOR (FGF) RECEPTOR SELECTIVE TYROSINE KINASE INHIBITOR E7090
-
April 8, 2019
START YOUR DAY WITH A SPARKLING POP!
EISAI TO LAUNCH CHOCOLA BB® SPARKLING KIWI & LEMON FLAVOR
CONTAINING 75 LEMONS WORTH OF VITAMIN C AND 50% LESS CALORIES!
-
April 5, 2019
“FOR MOTION SICKNESS AND DISCOMFORT”
EISAI TO LAUNCH “TRAVELMIN® SUPPORT” AS SERIES’ FIRST QUASI-DRUG
MOTION SICKNESS SOLUTION NOW AVAILABLE IN CONVENIENCE STORES
-
April 1, 2019
NICHI-IKO PHARMACEUTICAL AND EISAI COMMENCE CO-PROMOTION OF NICHI-IKO PRODUCTS AND COLLABORATION ON EISAI’S INTEGRATED PACKAGE STRATEGIES
-
March 29, 2019
DATA SAFETY MONITORING BOARD RECOMMENDS CONTINUATION OF PHASE III CLINICAL STUDIES OF BACE INHIBITOR ELENBECESTAT IN EARLY ALZHEIMER’S DISEASE
-
March 22, 2019
INITIATION OF PHASE III CLINICAL TRIAL OF BAN2401 IN EARLY ALZHEIMER’S DISEASE
-
March 22, 2019
EISAI TO PRESENT LATEST RESEARCH ON ALZHEIMER’S DISEASE / DEMENTIA PIPELINE AT THE 14TH INTERNATIONAL CONFERENCE ON ALZHEIMER’S & PARKINSON’S DISEASES
-
March 21, 2019
Biogen and Eisai to Discontinue Phase 3 ENGAGE and EMERGE Trials of aducanumab in Alzheimer’s Disease
Independent data monitoring committee advises aducanumab unlikely to meet primary endpoints, leading to decision to discontinue the trials
-
March 12, 2019
Eisai and Imbrium Therapeutics Announce U.S. FDA Filing Acceptance of New Drug Application for Lemborexant for the Treatment of Insomnia
-
March 7, 2019
MARKETING AUTHORIZATION APPLICATION FOR POTENTIAL INSOMNIA DISORDER TREATMENT LEMBOREXANT SUBMITTED IN JAPAN
-
February 27, 2019
EISAI ENTERS INTO AGREEMENT TO SUPPORT INTERNATIONAL NGO ASSOCIATION FOR AID AND RELIEF, JAPAN’S ACTIVITIES IN SUDAN
CONTRIBUTING FURTHER TO PATIENTS WITH MYCETOMA, A NEGLECTED TROPICAL DISEASE
-
February 21, 2019
AbbVie and Eisai Announce Fully Human Anti-TNF-α Monoclonal Antibody HUMIRA® is the First in Japan to be Approved for the Treatment of Hidradenitis Suppurativa
-
February 13, 2019
EISAI SUBMITS APPLICATION IN EUROPE SEEKING APPROVAL FOR FYCOMPA® AS TREATMENT FOR PEDIATRIC PATIENTS WITH EPILEPSY
-
February 4, 2019
Eisai and Purdue Pharma Present Efficacy and Safety Data from Second Pivotal Phase 3 Study at the Sleep Research Society’s Conference: Advances in Sleep and Circadian Science
Six-month data show significant improvements in patient-reported measures of sleep onset and sleep maintenance for investigational agent lemborexant
-
January 30, 2019
SUPPLEMENTARY NEW DRUG APPLICATION SUBMITTED IN JAPAN FOR FYCOMPA® AS MONOTHERAPY FOR PARTIAL-ONSET SEIZURES, PEDIATRIC INDICATION FOR PARTIAL-ONSET SEIZURES, AS WELL AS NEW FORMULATION
-
January 22, 2019
EISAI LISTED AS A GLOBAL 100 MOST SUSTAINABLE CORPORATION FOR THE FOURTH TIME
HIGHEST RANKED JAPANESE COMPANY
-
January 18, 2019
Notification Regarding Results of Voluntary Retirement Program
-
January 15, 2019
New Drug Application for Insomnia Disorder Treatment Lemborexant Submitted in the United States
-
January 15, 2019
EISAI TO PRESENT RESULTS OF POST-HOC ANALYSES OF LENVIMA® (LENVATINIB) PHASE III REFLECT STUDY IN HEPATOCELLULAR CARCINOMA AT 2019 GASTROINTESTINAL CANCERS SYMPOSIUM
-
January 4, 2019
FOR DEALING WITH VIRUSES AND BACTERIA! ANTIMICROBIAL BARRIER THAT LASTS FOR 1 WEEK “ETAK® ANTIMICROBIAL SPRAYα” WINS NIKKEI BUSINESS DAILY AWARDS FOR SUPERIORITY AT THE 2018 NIKKEI SUPERIOR PRODUCTS AND SERVICES AWARDS
-
January 4, 2019
NEW DRUG APPLICATION FOR PERAMPANEL DESIGNATED FOR PRIORITY REVIEW BY CHINA NATIONAL MEDICAL PRODUCTS ADMINISTRATION FOR ADJUNCTIVE TREATMENT OF PARTIAL ONSET SEIZURES